284462-80-2

Basic information

• Product Name: 4-(2-carbamoyl-pyridin-4-yloxy)aniline
• Synonyms: 4-(2-carbamoyl-pyridin-4-yloxy)aniline;4-(4-AMINOPHENOXY)PYRIDINE-2-CARBOXAMIDE
• CAS NO: 284462-80-2
• Molecular Formula: C₁₂H₁₁N₃O₂
• Molecular Weight: 229.23464
• Mol File: 284462-80-2.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 462.5 °C at 760 mmHg
• Flash Point: 233.5 °C
• Appearance: /
• Density: 1.315 g/cm³
• Vapor Pressure: 9.85E-09mmHg at 25°C
• Refractive Index: 1.655
• PKA: 14.79±0.50(Predicted)
• CAS DataBase Reference: 4-(2-carbamoyl-pyridin-4-yloxy)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-carbamoyl-pyridin-4-yloxy)aniline(284462-80-2)
• EPA Substance Registry System: 4-(2-carbamoyl-pyridin-4-yloxy)aniline(284462-80-2)

Safety Data

• Hazardous Substances Data: 284462-80-2(Hazardous Substances Data)

Usage

General Description

4-(2-Carbamoyl-pyridin-4-yloxy)aniline is a chemical compound with the molecular formula C14H13N3O2. It is a derivative of aniline and contains a carbamoyl-pyridin-4-yloxy group. This chemical has various potential applications, such as in medicinal chemistry as a building block for drug discovery and development. It may also have uses in other fields such as materials science and chemical synthesis. Further research and testing may elucidate its full range of potential properties and applications.

InChI:InChI=1/C12H11N3O2/c13-8-1-3-9(4-2-8)17-10-5-6-15-11(7-10)12(14)16/h1-7H,13H2,(H2,14,16)

Upstream product

• 99586-65-9 4-chloropicolinamide 
• 123-30-8 4-amino-phenol 
• 176977-85-8 methyl 4-chloro-2-pyridinecarboxylate hydrochloride 
• 176977-85-8 methyl 4-chloropyridine-2-carboxylate hydrochloride 

Downstream Products

• 284461-74-1 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-2-pyridine carboxamide 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 99586-65-9 4-chloropicolinamide 

Relevant articles and documents

ARYL UREAS WITH ANGIOGENISIS INHIBITING ACTIVITY

This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.

DIARYL UREAS AND COMBINATIONS

The present invention provides methods for treating cancer in humans and other mammals comprising administering a chemotherapeutic agent, such as an interferon, and an aryl urea compound of Formula (I) : B-NH-C(O)-NH-L-M-L1-(Q)1-3 (I). In Formula (I), B and L and are each, independently, optionally substituted phenyl, naphthyl, a 5 or 6 membered monocyclic heteroaryl group, or an 8 to 10 membered bicyclic heteroaryl group; M is a bridging group. Each Q is independently C(O)R4, C(O)OR4 and C(O)NR4R5; and L' is optionally substituted phenyl, naphthyl, monocyclic heteroaryl or bicyclic heteroaryl, or a saturated or partially saturated, monocyclic or bicyclic carbocyclic moiety or heterocyclic moiety.

TREATMENT OF CANCERS WITH ACQUIRED RESISTANCE TO KIT INHIBITORS

The present invention provides compositions and methods for treating cancers ; which have acquired resistance to a KIT inhibitor by administering effective amounts of sorafenib.